Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women
NCT ID: NCT03090997
Last Updated: 2021-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
45 participants
INTERVENTIONAL
2018-02-15
2022-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group 1: Three-month administration of vitamin C 500 mg daily + placebo Group 2: Three-month administration of resveratrol 500 mg daily + placebo Group 3: Three months administration of vitamin C 500 mg daily and resveratrol 500 mg daily as antioxidant therapy.
All participants will be monitored monthly for a period of 3 months: glucose, insulin, uric acid, Homeostatic Model Assessment (HOMA), total cholesterol (TC), triglycerides (TGC), High density lipoproteins-cholesterol (HDL- C), low density lipoproteins-cholesterol (LDL), blood pressure, body mass index (BMI). The antioxidant efficiency in erythrocytes by the quantification of antioxidant enzymes (superoxide dismutase, catalase, glutathione reductase and glutathione peroxidase), as well as total antioxidant capacity in plasma. In order to corroborate the oxidative damage, the product of the lipoperoxidation malondialdehyde and the carbonylation of proteins will be evaluated by spectrophotometric techniques before and three months after the intervention.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
vitamin C (500 mg/day/orally) + placebo
vitamin C (500 mg / day) + placebo
Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
Group 2
resveratrol (500 mg/day/orally) + placebo
resveratrol (500 mg / day) + placebo
Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
Group 3
vitamin C (500 mg/day/orally) + resveratrol (500 mg/day/orally)
vitamin C (500 mg / day) and resveratrol (500 mg / day)
Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vitamin C (500 mg / day) + placebo
Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
resveratrol (500 mg / day) + placebo
Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
vitamin C (500 mg / day) and resveratrol (500 mg / day)
Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Insulin resistance determinated by HOMA ≥ 2.5.
* Not use of metformin, bezafibrates and / or statins, three months before enter to the study
* No indication of hormone replacement therapy.
* Sign the informed consent.
Exclusion Criteria
* Women who during the development of the protocol require hormone replacement therapy.
* Any type of surgical intervention during the following of the study.
* That the patient wishes to withdraw from the study.
* That the patient does not complete with 80% of adherence to the treatment
50 Years
60 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ENRIQUE REYES-Munoz MD
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Araceli Montoya-Estrada, PhD
Role: PRINCIPAL_INVESTIGATOR
Instituto Nacional de Perinatología Isidro Espinosa de los Reyes
Guillermo F Ortiz-Luna, MD
Role: STUDY_CHAIR
Instituto Nacional de Perinatología Isidro Espinosa de los Reyes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Nacional de Perinatología Isidro Espinosa de los Reyes
Mexico City, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3210-10209-01-574-17
Identifier Type: -
Identifier Source: org_study_id